{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:15:07Z","timestamp":1783160107174,"version":"3.54.6"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["4081\/25"],"award-info":[{"award-number":["4081\/25"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Biotechnology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.tibtech.2026.04.023","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:10:43Z","timestamp":1779163843000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioengineering CAR-T cells to function in hostile tumor microenvironments"],"prefix":"10.1016","author":[{"given":"Sara","family":"Mahajna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad","family":"Barhoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asala","family":"Sabbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilinca-Maria","family":"Igescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-8946","authenticated-orcid":false,"given":"Mohamed","family":"Mahameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tibtech.2026.04.023_bb0005","article-title":"Cell therapy: types, regulation, and clinical benefits","volume":"8","author":"El-Kadiry","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0010","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/d41573-025-00180-1","article-title":"Cancer cell therapies: global clinical trial trends and emerging directions","volume":"24","author":"Benthani","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0015","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0020","first-page":"180","article-title":"Living medicines engineered to fight: a comprehensive review on CAR T-cell therapy","volume":"19","author":"Vinoo","year":"2025","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00003495-200060020-00002","article-title":"Viral vectors for gene transfer: a review of their use in the treatment of human diseases","volume":"60","author":"Walther","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2025.169473","article-title":"Retroviral vector technology for gene therapy: history, current landscape, and future prospects","volume":"437","author":"Jaballah","year":"2025","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape\u2014lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0060","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0065","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","article-title":"Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"Med"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0070","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3389\/fimmu.2018.02486","article-title":"Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology","volume":"9","author":"Watanabe","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.766275","article-title":"Deciphering tumor niches: lessons from solid and hematological malignancies","volume":"12","author":"Mancini","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0080","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/cancers13020284","article-title":"Hematopoietic versus solid cancers and T cell dysfunction: looking for similarities and distinctions","volume":"13","author":"Montironi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0085","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0090","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-024-03817-z","article-title":"Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells","volume":"74","author":"Khaliulin","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0120","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0125","doi-asserted-by":"crossref","first-page":"17536","DOI":"10.3390\/ijms242417536","article-title":"Insights into the tumor microenvironment\u2014components, functions and therapeutics","volume":"24","author":"Baghy","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0130","article-title":"The solid tumor microenvironment and related targeting strategies: a concise review","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0135","article-title":"Tumor microenvironment and its role in cancer progression: an integrative review","volume":"17","author":"Almazrouei","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115206","article-title":"Tumor-induced metabolic immunosuppression: mechanisms and therapeutic targets","volume":"44","author":"Ricci","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0145","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.adro.2018.08.018","article-title":"Role of the immunosuppressive microenvironment in immunotherapy","volume":"3","author":"Tormoen","year":"2018","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0150","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3389\/fimmu.2020.00940","article-title":"The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses","volume":"11","author":"Labani-Motlagh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.830208","article-title":"Key players of the immunosuppressive tumor microenvironment and emerging therapeutic strategies","volume":"10","author":"Park","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0160","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12026-025-09687-6","article-title":"Engineering CAR-T cells for solid tumors: bispecific antigen targeting, tumor microenvironment modulation, and toxicity control","volume":"73","author":"Premchandani","year":"2025","journal-title":"Immunol. Res."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0165","article-title":"Engineering CAR-T therapeutics for enhanced solid tumor targeting","volume":"37","author":"Zhu","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1574742","article-title":"CAR-NK cell therapy: promise and challenges in solid tumors","volume":"16","author":"Balkhi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0175","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41698-025-01170-7","article-title":"CAR-macrophages in solid tumors: promise, progress, and prospects","volume":"9","author":"Alrehaili","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-025-01744-9","article-title":"Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?","volume":"18","author":"Vo","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/curroncol32020079","article-title":"Tumor-associated extracellular matrix obstacles for CAR-T cell therapy: approaches to overcoming","volume":"32","author":"Klabukov","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1638186","article-title":"Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling","volume":"16","author":"Andreou","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0195","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0200","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/febs.14466","article-title":"A guide to chemokines and their receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0205","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0210","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0215","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00018-025-05972-7","article-title":"CCR2\/CXCR6 enhances tumor infiltration and antitumor efficacy of MSLN CAR-T cells","volume":"83","author":"Zhang","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0225","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00262-024-03909-w","article-title":"CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors","volume":"74","author":"Tian","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0230","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: a review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0235","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3390\/cells14221825","article-title":"A comprehensive review of modern cancer therapies utilizing oncolytic viruses","volume":"14","author":"Su\u0142ek","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0240","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: a current review","volume":"10","author":"Santos Apolonio","year":"2021","journal-title":"World J. Virol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0245","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011783","article-title":"hCCL19-expressing recombinant Newcastle disease virus boosts CAR T cell infiltration and efficacy in solid tumor","volume":"13","author":"Liu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0250","doi-asserted-by":"crossref","first-page":"18465","DOI":"10.1074\/jbc.RA119.011134","article-title":"Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding","volume":"294","author":"Mondal","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.573823","article-title":"Intercellular adhesion molecule-1 as target for CAR-T-cell therapy of triple-negative breast cancer","volume":"11","author":"Wei","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188356","article-title":"Fibrosis and cancer: a strained relationship","volume":"1873","author":"Piersma","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0265","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","article-title":"The interplay between extracellular matrix remodeling and cancer therapeutics","volume":"14","author":"Prakash","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0270","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40164-025-00647-2","article-title":"Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0275","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0280","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1021\/acscentsci.2c00163","article-title":"Bioorthogonal equipping CAR-T cells with hyaluronidase and checkpoint blocking antibody for enhanced solid tumor immunotherapy","volume":"8","author":"Zhao","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0285","article-title":"Human hyaluronidase PH20 potentiates the antitumor activities of mesothelin-specific CAR-T cells against gastric cancer","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0290","article-title":"Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors","volume":"4","author":"Jung","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0295","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.semcancer.2021.12.011","article-title":"Multifaceted role of chemokines in solid tumors: from biology to therapy","volume":"86","author":"Raza","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0300","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0305","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0310","doi-asserted-by":"crossref","first-page":"9745","DOI":"10.3390\/ijms26199745","article-title":"The duality of collagens in metastases of solid tumors","volume":"26","author":"Carnazza","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0315","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0325","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0330","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0335","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0340","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1901434","article-title":"Construction of PD1\/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer","volume":"10","author":"Chen","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104311","article-title":"The cytokines in tumor microenvironment: from cancer initiation-elongation-progression to metastatic outgrowth","volume":"196","author":"Pradhan","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0350","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0355","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nrc3603","article-title":"The roles of TGF\u03b2 in the tumour microenvironment","volume":"13","author":"Pickup","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114697","article-title":"Targeting immunosuppression by TGF-\u03b21 for cancer immunotherapy","volume":"192","author":"de Streel","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0365","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0370","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","article-title":"Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0375","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 engineering improves CAR T cell function in solid tumors","volume":"38","author":"Ma","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0380","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0385","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0390","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted t cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0395","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1158\/0008-5472.CAN-18-0030","article-title":"CRISPR\/Cas9-mediated knockout of DGK improves antitumor activities of human T cells","volume":"78","author":"Jung","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0400","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001688","article-title":"Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function","volume":"9","author":"Kumar","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0405","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2016.04.001","article-title":"Immunosuppressive activities of adenosine in cancer","volume":"29","author":"Allard","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0410","doi-asserted-by":"crossref","first-page":"14928","DOI":"10.3390\/ijms241914928","article-title":"The immune regulatory role of adenosine in the tumor microenvironment","volume":"24","author":"Xing","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0415","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ni1001-907","article-title":"Nitric oxide and the immune response","volume":"2","author":"Bogdan","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0420","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-3-030-50224-9_10","article-title":"Tumor microenvironment and nitric oxide: concepts and mechanisms","volume":"1277","author":"Vedenko","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0425","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0430","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1824643","article-title":"Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway","volume":"9","author":"Li","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112886","article-title":"Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo","volume":"409","author":"Liu","year":"2021","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0440","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1021\/acsnano.5c06907","article-title":"Engineering T cells with membrane-anchored nitric oxide scavengers for anticancer therapy","volume":"20","author":"Lee","year":"2026","journal-title":"ACS Nano"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0445","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","article-title":"Exhaustion of CAR T cells: potential causes and solutions","volume":"20","author":"Kouro","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0450","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2021.06.012","article-title":"The role of exhaustion in CAR T cell therapy","volume":"39","author":"Delgoffe","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0455","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ymthe.2024.04.004","article-title":"Decoding and overcoming T cell exhaustion: epigenetic and transcriptional dynamics in CAR-T cells against solid tumors","volume":"32","author":"Ahn","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0460","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0465","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0470","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008665","article-title":"NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors","volume":"12","author":"Nakagawara","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0475","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3390\/cancers11081191","article-title":"Reactive oxygen species in the tumor microenvironment: an overview","volume":"11","author":"Weinberg","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189154","article-title":"Reactive oxygen species of tumor microenvironment: harnessing for immunogenic cell death","volume":"1879","author":"Malla","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.cstres.2025.100108","article-title":"Reactive oxygen species in cancer: mechanistic insights and therapeutic innovations","volume":"30","author":"Ma","year":"2025","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0490","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3390\/cancers12071748","article-title":"Reactive oxygen species and antitumor immunity-from surveillance to evasion","volume":"12","author":"Kotsafti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0495","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4049\/jimmunol.1401710","article-title":"Coexpressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity","volume":"196","author":"Ligtenberg","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0500","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0505","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1331355","article-title":"Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours","volume":"14","author":"Bigos","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0510","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","article-title":"Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0515","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/med.70015","article-title":"Arginine competition in tumor microenvironment: a potential target for cancer therapy","volume":"46","author":"Zhang","year":"2025","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217680","article-title":"The arginine metabolism and its deprivation in cancer therapy","volume":"620","author":"Feng","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0525","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood.2019004500","article-title":"Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity","volume":"136","author":"Fultang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tibtech.2026.04.023_bb0530","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.omto.2020.01.008","article-title":"Inhibition of cholesterol esterification enzyme enhances the potency of human chimeric antigen receptor T cells against pancreatic carcinoma","volume":"16","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0535","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/CJI.0000000000000207","article-title":"Cholesterol esterification enzyme inhibition enhances antitumor effects of human chimeric antigen receptors modified T cells","volume":"41","author":"Zhao","year":"2018","journal-title":"J. Immunother."},{"key":"10.1016\/j.tibtech.2026.04.023_bb0540","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006522","article-title":"Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor T-cell therapy against solid tumors","volume":"11","author":"Lontos","year":"2023","journal-title":"J. Immunother. Cancer"}],"container-title":["Trends in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926001770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926001770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:16:50Z","timestamp":1783156610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167779926001770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":108,"alternative-id":["S0167779926001770"],"URL":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.04.023","relation":{},"ISSN":["0167-7799"],"issn-type":[{"value":"0167-7799","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioengineering CAR-T cells to function in hostile tumor microenvironments","name":"articletitle","label":"Article Title"},{"value":"Trends in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}